Rapid control of secondary hyperparathyroidism with paricalcitol (Zemplar®) capsule in patients on peritoneal dialysis.

被引：0
|
作者：
Qiu, P
Smolenski, O
Fadem, S
Kant, KS
Borneman, L
Hippensteel, R
Williams, LA
Moe, S
机构：
[1] GPRD, Abbott Labs, Abbott Pk, IL USA
[2] Washington Univ, St Louis, MO USA
[3] Nephrol Hosp B Rydygier, Krakow, Poland
[4] Univ Tennessee, Memphis, TN USA
[5] Kidney Associates, Houston, TX USA
[6] Univ Cincinnati, Dialysis Clin Inc, Cincinnati, OH USA
[7] Indiana Univ, Indianapolis, IN 46204 USA
来源：
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY | 2003年 / 14卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：484A / 484A
页数：1
相关论文
共 50 条
  • [31] Optimization of calcitriol dosis in the treatment of secondary hyperparathyroidism in dialysis.: Six month results
    García, MR
    Martín, JLF
    de Castañeda, JR
    Sánchez, JH
    Andía, JBC
    [J]. NEFROLOGIA, 2002, 22 (04): : 370 - 376
  • [32] New findings confirm Zemplar reduces effects of secondary hyperparathyroidism in CRF patients
    不详
    [J]. DIALYSIS & TRANSPLANTATION, 2000, 29 (06) : 311 - 311
  • [33] Paricalcitol in hemodialysis patients with secondary hyperparathyroidism and its potential benefits
    Xiu Chen
    Feng Zhao
    Wei-Juan Pan
    Jia-Mei Di
    Wei-Nan Xie
    Ling Yuan
    Zhi Liu
    [J]. World Journal of Clinical Cases, 2021, (33) : 10172 - 10179
  • [34] Efficacy of Paricalcitol in the Treatment of Secondary Hyperparathyroidism in Maintenance Hemodialysis Patients
    Ou, Santao
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2022, 33 (11): : 920 - 920
  • [35] Treatment of secondary hyperparathyroidism with paricalcitol with or without cinacalcet in hemodialysis patients
    Zawierucha, Jacek
    Malyszko, Jolanta
    Malyszko, Jacek S.
    Prystacki, Tomasz
    Marcinkowski, Wojciech
    Dryl-Rydzynska, Teresa
    [J]. POLISH ARCHIVES OF INTERNAL MEDICINE-POLSKIE ARCHIWUM MEDYCYNY WEWNETRZNEJ, 2017, 127 (12): : 840 - 845
  • [36] Effective treatment of secondary hyperparathyroidism with paricalcitol in chronic hemodialysis patients
    Kampouris, H.
    Orfanaki, G.
    Kapsos, A.
    Rudenko, I.
    Grekas, D.
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2006, 21 : 131 - 131
  • [37] Paricalcitol in hemodialysis patients with secondary hyperparathyroidism and its potential benefits
    Chen, Xiu
    Zhao, Feng
    Pan, Wei-Juan
    Di, Jia-Mei
    Xie, Wei-Nan
    Yuan, Ling
    Liu, Zhi
    [J]. WORLD JOURNAL OF CLINICAL CASES, 2021, 9 (33) : 10172 - 10179
  • [38] FIXED DOSES OF PARICALCITOL AND CINACALCET IN THE THERAPY OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS ON MAINTENANCE DIALYSIS-OUR INITIAL EXPERIENCE
    Veljancic, Ljubisa
    Radojevic, Milorad
    Paunic, Zoran
    Vavic, Neven
    Obrencevic, Katarina
    Kovacevic, Zoran
    Pejovic, Janko
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2012, 27 : 510 - 510
  • [39] Randomized controlled trial to compare the efficacy and safety of oral paricalcitol with oral calcitriol in dialysis patients with secondary hyperparathyroidism
    Ong, Loke Meng
    Narayanan, Punithavathi
    Goh, Heong Keong
    Manocha, Anita Bhajan
    Ghazali, Ahmad
    Omar, Mahanim
    Mohamad, Sukeri
    Goh, Bak-Leong
    Shah, Shahnaz
    Seman, Mohd Ramli
    Vaithilingam, Indralingam
    Ghazalli, Rozina
    Rahmat, Korina
    Shaariah, Wan
    Ching, Chen Hua
    [J]. NEPHROLOGY, 2013, 18 (03) : 194 - 200
  • [40] Effect of paricalcitol on biochemical markers of secondary hyperparathyroidism in hemodialysis patients
    Zdravkovic, J.
    Georgijev, D. Ristic
    Zdravkovic, A.
    Zdravkovic, K.
    Popovic, M.
    Stojanovic, S.
    [J]. CLINICA CHIMICA ACTA, 2024, 558
12345